SYNkinase established in 2008, is a primary producer of research-use-only biomedical reagents, which it markets to life science and drug discovery researchers at universities, research institutes and industry. The founders of the company have been involved in pharmaceutical drug discovery for three decades and include kinase biology scientists and expert medicinal and synthetic chemists.

SYNkinase provides life science researchers with a library of kinase inhibitors, and other small molecule inhibitors of important therapeutic proteins for drug discovery research use. They offer a library of potent, pure and research-relevant inhibitors directed against specific protein serine/threonine kinases (PS/TKs), protein tyrosine kinases (PTK & RTK) as well as lipid kinases.

There are more than 150 kinase targeted drugs in clinical trials or development at present. Twenty-four small molecule inhibitors have been FDA-approved including mTOR, BRaf, MEK, EGFR, JAK, VEGFR and PI3K inhibitors. SYNkinase has many of these compounds available for sale as well as a large range of inhibitors described in the literature such as GPCR, TGF-β, MAP kinase, cell cycle and epigenetic inhibitors.

SYNkinase is a part of AdipoGen Life Sciences, who also cooperates with a number of other manufacturers such as: AbFrontier, Ancell CorporationBioActs, BioViotica, Chemodex, Chimerigen Laboratories, Innaxon, JaICA, and South Bay Bio.

SYNkinase: Your first choice for small molecule inhibitors

Major product lines

  • Kinase inhibitors
  • Small molecule inhibitors
  • Epigenetics
  • GPCRs
  • Affinity probes
Cat. No.Description

Cell cycle inhibitors

SYN-1010AT7519 hydrochloride [902135-91-5]
SYN-1023BMS-3 [1338247-30-5]
SYN-1080BMS-387032 hydrochloride [345627-90-9]
SYN-1024BMS-5 [1338247-35-0]
SYN-1109CX-4945 [1009820-21-6]
SYN-1061PD-173955 [260415-63-2]
SYN-1070Purvalanol B [212844-54-7]
SYN-1081SNS-314 [1057249-41-8]

Growth factor inhibitors

SYN-1004AG-13958 [319460-94-1]
SYN-1125AMG-25 [1003311-62-3]
SYN-1008AMG-Tie2-1 [870223-96-4]
SYN-1012AV-412 [451492-95-8]
SYN-1033CP-724714 [383432-38-0]
SYN-1133JNJ-38158471 [951151-97-6]
SYN-1055Motesanib [453562-69-1]
SYN-1169Regorafenib [835621-08-4]
SYN-1165SAR-131675 [1092539-44-0]
SYN-1168Takeda-6d [1125632-93-0]
SYN-1013Tivozanib [475108-18-0]

JAK/STAT pathway inhibitors

SYN-1117Baricitinib phosphate salt [1187595-84-1]
SYN-1130Bayer-18 [1251752-12-1]
SYN-1156CEP-33779 [1346168-57-7]
SYN-1182CX-6258 [1202916-90-2]
SYN-1158GLPG0634 [1206161-97-8]
SYN-1124GSK25 [874119-56-9]
SYN-1054Merck-5 [457081-03-7]
SYN-1136NVP-BSK805 dihydrochloride [1092499-93-8]
SYN-1062PD-173955-Analog1 [185039-99-0]
SYN-1163PF-4618433 [1166393-85-6]
SYN-1204PRT-060318 [1194961-19-7]
SYN-1128RO495 [1258296-60-4]
SYN-1203TAK-632 [1228591-30-7]
SYN-1106TG-46 [936091-15-5]
SYN-1107TG-89 [936091-56-4]
SYN-1191XL019 [945750-13-0]

MAPK pathway inhibitors

SYN-1007AMG-47a [882663-88-9]
SYN-1147Bentamapimod [848344-36-5]
SYN-1028CC-401 hydrochloride [395104-30-0]
SYN-1188CH4987655 [874101-00-5]
SYN-1072RWJ-67657 [215303-72-3]
SYN-1119S-99 [1124381-69-6]
SYN-1076SB-242235 [193746-75-7]
SYN-1078SD-06 [271576-80-8]
SYN-1079SD-169 [1670-87-7]

PI3K/AKT/mTOR pathway inhibitors

SYN-1110A-674563 hydrochloride [552325-73-2]
SYN-1005Akt-I-1 [473382-39-7]
SYN-1006Akt-I-2 hydrochloride [473382-48-8]
SYN-1143AMG-1 [913376-84-8]
SYN-1111AMG-51 [890019-63-3]
SYN-1210AST-487 [1337531-89-1]
SYN-1160AZD-26 [1357158-81-6]
SYN-1197BLZ-945 [953769-46-5]
SYN-1202GDC-0032 [1282512-48-4]
SYN-1148GNE-477 [1032754-81-6]
SYN-1114GNE-490 [1033739-92-2]
SYN-1115GNE-493 [1033735-94-2]
SYN-1205KW-2449 hydrochloride [841259-17-4]
SYN-1145NIBR-17 [944396-88-7]
SYN-1067PIK-75 [372196-67-3]
SYN-1068PIK-90 [677338-12-4]
SYN-1132S6K-18 [1265789-88-5]
SYN-1155SGX-523 [1072116-01-8]
SYN-1208TASP0415914 [1292300-75-4]

For more information, please visit: Adipogen-SYNkinase

Product groups

  • Chemicals »»